Cancer Type | Expression of Necroptotic Factors | The Influence on Prognosis | Reference |
---|---|---|---|
Breast Cancer | decreased RIPK3 expression | worse prognosis | |
Colorectal Cancer | decreased RIPK3 expression; decreased MLKL expression | reduced DFS and OS; reduced OS | |
Acute Myeloid Leukemia | decreased RIPK3 expression | accelerated leukemogenesis and worse survival | |
Melanoma | decreased RIPK3 expression; decreased CYLD expression | not mentioned; enhanced tumor progression and metastasis | |
Head and Neck Squamous Cell Carcinoma | decreased RIPK1 expression | enhanced tumorigenesis | [9] |
Chronic Lymphocytic Leukemia | decreased CYLD expression | reduced OS | [71] |
Glioblastoma | increased RIPK1 expression | worse prognosis | [10] |
Lung Cancer | increased RIPK1 expression | promoted oncogenesis | [72] |
Pancreatic Cancer | increased expression of RIPK1, RIPK3, FADD and MLKL | promoted oncogenesis | |
Gastric Cancer | decreased MLKL expression | reduced OS | [74] |
Ovarian Cancer | Decreased MLKL expression | reduced OS | [75] |
Cervical Squamous Cell Carcinoma | decreased MLKL expression | reduced OS | [76] |